We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Theravance Biopharma, Inc. (TBPH - Free Report) . Shares have lost about 7.7 % in that time frame.
Will the recent negative trend continue leading up to its next earnings release, or is TBPH due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Theravance Biopharma Q4 Loss Wider, Sales Drop Y/Y
Theravance Biopharma reported fourth-quarter 2017 loss of $1.64 per share, wider than both the Zacks Consensus Estimate of a loss of $1.15 and the year-ago loss of $1.36.
Total revenues in the quarter plunged 21.1% year over year to $4.5 million compared with the prior-year figure. This downside can mainly be attributed to lower sales from the company’s sole marketed product, Vibativ. However, the top line surpassed the Zacks Consensus Estimate of $4 million.
Quarterly Details
Vibativ generated U.S. revenues of $4.1 million in the fourth quarter, down 18% from the year-ago period. Sales decreased mainly due to the impact of generic competition in the United States.
Revenues from collaborations were $0.4 million compared with $0.7 million in the year-earlier quarter.
Research and development expenses were $51 million, up 21.4% from the year-ago period, mainly due to increases in employee-related costs and advancement of the company’s priority pipeline programs, partially offset by reduction in external expenses.
Selling, general & administrative expenses rose 44.6% to $20.9 million, primarily on higher employee-related costs.
2017 Results
Full-year sales slumped 68.3% year over year to $15.4 million. However, the number beat the Zacks Consensus Estimate of $14.5 million.
Full-year loss of $5.45 per share was wider than the year-ago tally of $4.26. Loss was also wider than the consensus mark of a loss of $4.85.
2018 Outlook
Theravance projects operating loss for 2018 in the range of $180-$200 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimate flatlined during the past month. There has been one revision higher for the current quarter compared to one lower.
At this time, TBPH has a poor Growth Score of F. Its Momentum is doing a bit better with a D. The stock was also allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
TBPH has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Theravance Biopharma, Inc. (TBPH - Free Report) . Shares have lost about 7.7 % in that time frame.
Will the recent negative trend continue leading up to its next earnings release, or is TBPH due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Theravance Biopharma Q4 Loss Wider, Sales Drop Y/Y
Theravance Biopharma reported fourth-quarter 2017 loss of $1.64 per share, wider than both the Zacks Consensus Estimate of a loss of $1.15 and the year-ago loss of $1.36.
Total revenues in the quarter plunged 21.1% year over year to $4.5 million compared with the prior-year figure. This downside can mainly be attributed to lower sales from the company’s sole marketed product, Vibativ. However, the top line surpassed the Zacks Consensus Estimate of $4 million.
Quarterly Details
Vibativ generated U.S. revenues of $4.1 million in the fourth quarter, down 18% from the year-ago period. Sales decreased mainly due to the impact of generic competition in the United States.
Revenues from collaborations were $0.4 million compared with $0.7 million in the year-earlier quarter.
Research and development expenses were $51 million, up 21.4% from the year-ago period, mainly due to increases in employee-related costs and advancement of the company’s priority pipeline programs, partially offset by reduction in external expenses.
Selling, general & administrative expenses rose 44.6% to $20.9 million, primarily on higher employee-related costs.
2017 Results
Full-year sales slumped 68.3% year over year to $15.4 million. However, the number beat the Zacks Consensus Estimate of $14.5 million.
Full-year loss of $5.45 per share was wider than the year-ago tally of $4.26. Loss was also wider than the consensus mark of a loss of $4.85.
2018 Outlook
Theravance projects operating loss for 2018 in the range of $180-$200 million.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimate flatlined during the past month. There has been one revision higher for the current quarter compared to one lower.
Theravance Biopharma, Inc. Price and Consensus
Theravance Biopharma, Inc. Price and Consensus | Theravance Biopharma, Inc. Quote
VGM Scores
At this time, TBPH has a poor Growth Score of F. Its Momentum is doing a bit better with a D. The stock was also allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
TBPH has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.